Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 5Rectal Neoplasms 4Pancreatic Neoplasms 4Carcinoma, Hepatocellular 4Colonic Neoplasms 3Liver Neoplasms 2Gallbladder Neoplasms 2Bile Duct Neoplasms 2Stomach Neoplasms 1Neurotoxicity Syndromes 1Neoplasms 1Neoplasm Metastasis 1Gastrointestinal Stromal Tumors 1Gastrointestinal Neoplasms 1Esophageal Neoplasms 1Appendiceal Neoplasms 1Anus Neoplasms 1

Interventions

Oxaliplatin 6Sodium Chloride 3Leucovorin 3Fluorouracil 3xaliproden 2Magnesium Sulfate 2Folfox protocol 2Calcium Gluconate 2neurotropin 1Pharmacogenomic Testing 1Gene Expression Profiling 1Capecitabine 1Bevacizumab 1Acupuncture Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neurotoxicity Syndromes × Pharmacogenomic Testing × Gastrointestinal × Clear all
NCT00884767 2009-07-08

Biomarkers in Predicting Neurotoxicity in Patients With Colorectal Cancer Receiving Oxaliplatin

National Cancer Institute (NCI)

Phase 2 Unknown
206 enrolled
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Neurotoxicity Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡